In the cellular context, C3I-22 treatment reduced the levels of pRb and CDK4 (Figure 9A and Supplemental Figure 7A) and caused the failure of rapid cell cycle progression in cancer cells as shown by flow cytometry (Figure 9, B and C, and Supplemental Figure 7, B and C). Here, CDK4 is linked to cancer.